KIT and neoplasm: After the proposal of TOC for the treatment of canine mast cell tumors, several papers have investigated separately the expression of c-KIT, VEGFR-2, and PDGFR-β by IHC in different tumor subtypes (without clinical treatment) claiming that IHC expression could predict TOC therapy [28,29,30].